Bioactivatable Chalcogenide Coatings for Controlled Copper Chelation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing medical device coatings, particularly drug-eluting stents, face challenges with prolonged development times, increased costs, regulatory complexities, and limited therapeutic efficacy due to unpredictable drug release profiles and solubility issues of transition metal chalcogenides, leading to adverse tissue reactions and repeated interventions.
Innovation Solution
Development of bioactivatable devices using transition metal chalcogenides, such as molybdenum sulfides, that convert in vivo from a non-bioactive to a bioactive state, exhibiting copper-chelating activities to promote anti-inflammatory and anti-proliferative effects, thereby extending therapeutic duration and improving biocompatibility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If transition metal chalcogenides are used in medical device coatings, then copper-chelating activity and anti-inflammatory effects are improved, but solubility control and predictable release profiles deteriorate
Solution Approach 1:
The patent applies parameter changes by systematically varying the composition ratios of transition metal chalcogenides (e.g., MoS2, WS2, WSe2) and controlling their crystalline structures to achieve desired solubility profiles. By adjusting these material parameters, the coating maintains stability during storage while enabling controlled copper chelating activity upon implantation.
Solution Approach 2:
The invention uses composite materials by combining transition metal chalcogenides with biocompatible polymers or ceramic matrices. This composite approach allows the active transition metal compounds to be embedded in a stable carrier that controls their release kinetics, thereby achieving both reliable copper-chelating activity and predictable release profiles.
2Reliability
If drug-eluting stents with polymeric matrices are used, then therapeutic effects are improved, but development time and manufacturing complexity increase
Solution Approach 1:
The patent extracts the active therapeutic component (transition metal chalcogenide) from complex polymeric drug delivery systems. By using physical vapor deposition or chemical vapor deposition to directly deposit the active material onto the stent surface, the invention eliminates the need for complex polymer matrix formulation, mixing, and coating processes, thereby reducing development time and manufacturing complexity.
Solution Approach 2:
The invention replaces mechanical mixing and polymer-based drug delivery systems with vapor deposition techniques. This substitution allows for direct, uniform coating of the active material without requiring complex polymer formulations, simplifying the manufacturing process while maintaining therapeutic efficacy.
3Object-affected harmful factors
If conventional biocompatible coatings are applied, then immediate biocompatibility is improved, but sustained therapeutic duration deteriorates
Solution Approach 1:
The patent applies preliminary action by depositing a thin layer of transition metal chalcogenide coating on the medical device surface before implantation. This pre-applied coating serves as a reservoir that gradually releases copper-chelating agents over an extended period, providing both immediate biocompatibility upon implantation and sustained therapeutic effects throughout the healing process.
Solution Approach 2:
The invention achieves continuity of useful action through the gradual, sustained release of copper-chelating agents from the transition metal chalcogenide coating. Unlike conventional coatings that provide only immediate protection, this coating continuously releases therapeutic agents over weeks or months, maintaining biocompatibility and anti-inflammatory effects throughout the entire implant integration period.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bioactivatable devices provide sustained therapeutic effects by modulating copper-dependent biological reactions, reducing inflammation, and preventing tissue damage, thus enhancing the longevity and efficacy of medical implants.
Implementation Method 1
transition metal chalcogenides, such as molybdenum sulfides, that can be converted in vivo from a non-bioactive state to a bioactive state
Implementation Method 2
the bioactivated transition metal chalcogenide derivatives, such as molybdenum sulfide derivatives, can exhibit copper-chelating activities
Data Source
AI summary
The present disclosure is related to inorganic, biocompatible material compositions for bioactivatable devices, devices, and products comprising transition metal chalcogenides, such as molybdenum sulfides, that can be converted in vivo from a non-bioactive state to a bioactive state upon exposure to physiological conditions, wherein the bioactivated transition metal chalcogenide derivatives, such as molybdenum sulfide derivatives, exhibit copper-chelating activities. Various methods for the application of these compositions for enhancing biocompatibility and reducing or modulating copper-dependent biological reactions are provided.